BiotechTube

ZYH7 + ZYH7 + ZYH7 + Fenofibrate

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hypertriglyceridemia

Conditions

Hypertriglyceridemia, Dyslipidemia

Trial Timeline

Nov 1, 2011 → Aug 1, 2012

NCT ID
NCT01539616

About ZYH7 + ZYH7 + ZYH7 + Fenofibrate

ZYH7 + ZYH7 + ZYH7 + Fenofibrate is a phase 2 stage product being developed by Zydus Lifesciences for Hypertriglyceridemia. The current trial status is completed. This product is registered under clinical trial identifier NCT01539616. Target conditions include Hypertriglyceridemia, Dyslipidemia.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT01539616Phase 2Completed

Competing Products

20 competing products in Hypertriglyceridemia

See all competitors
ProductCompanyStageHype Score
LY3875383 + PlaceboEli LillyPhase 1
33
Solbinsiran + PlaceboEli LillyPhase 2
52
Placebo + Ethyl IcosapentateSumitomo PharmaPhase 3
77
Omega-3-Acid Ethyl Esters 90 Soft Capsules + Corn OilJiangsu Hengrui MedicinePhase 3
77
warfarin + omefas + omega-3-acid ethyl estersAstraZenecaPhase 1
33
rosuvastatinAstraZenecaApproved
85
Simvastatin + acetylsalicylic acid (ASA) + omefasAstraZenecaPhase 1
33
Olive oil, 4g + omega-3-carboxylic acids, 2g + omega-3-carboxylic acids, 4gAstraZenecaPhase 3
77
Epanova (4 g) and Lovaza (4 g) + Lovaza (4 g) and Epanova (4 g)AstraZenecaPhase 2
52
rosuvastatin 40 mg tablet + Epanova™ QD (2 x 1 g capsules) + Multiple doses of 4 g Epanova™ with single of rosuvastatin 40 mg dose + Multiple (20) oral doses of 2 g Vascepa® every 12 hoursAstraZenecaPhase 1
33
placebo + omefas + omefas + omefasAstraZenecaPhase 2/3
65
Epanova + LovazaAstraZenecaPhase 1
33
Epanova + Olive OilAstraZenecaPhase 3
77
AZD0585 + AZD0585 placeboAstraZenecaPhase 3
77
ABT-143 + simvastatinAstraZenecaPhase 3
77
MaravirocPfizerPhase 1
32
torcetrapib/atorvastatin + atorvastatinPfizerPhase 3
76
Icosapent (MND-2119) + Icosapent (EPADEL CAPSULES 300)Mochida PharmaceuticalPhase 3
76
IcosapentMochida PharmaceuticalPhase 3
76
REGN1500 + placeboRegeneron PharmaceuticalsPhase 1
32

Other Products from Zydus Lifesciences

SaroglitazarApproved
85
DesidustatApproved
85
Desidustat Oral Tablet + Epoetin AlfaPhase 3
77
Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel + DUAC® Gel + PlaceboPhase 3
77
Pertuzumab (ZRC-3277) + Pertuzumab (Perjeta®)Phase 3
77